The history of coxibs, precariousness and certainties;Histoire des coxibs, précarité des certitudes

Presse Medicale

Volumn 31, Issue 31, 2002, Pages 1444-1445

  Bouvenot, Gilles ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ROFECOXIB;

ANTIINFLAMMATORY ACTIVITY; DRUG TOLERANCE; EDITORIAL; ENDOSCOPY; HUMAN; INFLAMMATION; STATISTICAL ANALYSIS; STOMACH ULCER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; DRUG APPROVAL; FRANCE; HISTORY, 20TH CENTURY; HUMANS; RISK FACTORS;

EID: 0037190478     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (12)

1. http//www.cnamts.fr/secu/fichiers/Medicam20002001.pdf
2. Silverstein F, Faich G, Goldstein J et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000; 284: 1247-1255.
3. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis N Engl J Med 2000; 343: 1520-8.
4. Berg Hrachovec J, Mora M. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. To the editor JAMA 2001; 286: 2398
5. Wright JM, Perry TL, Bassett KL, Chambers GK. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. To the editor JAMA 2001; 286: 2398-9
6. Gottlieb S. Researchers deny any attempt to mislead the public over JAMA article on arthritis drug. BMJ 2001; 323: 301.
7. Silverstein F, Simon L, Faich G Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. In reply JAMA 2001; 286: 2399-400
8. Mukherjee D, Nissen SE, Topol EJ Risk of cardiovascular events associated with selective COX 2 inhibitors JAMA 2001; 286: 954-9
9. AFSSAPS communiqués de presse (Recommandations sur la prescription et la surveillance d'un traitement par Coxib; Réévaluation des anti-inflammatoires inhibiteurs de la COX-2; rofecoxib et celecoxib et risque d'événements cardiovasculaires, http//agmed.sante.gouv.fr
10. Juni P, Rutjes AW, Dieppe PA Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ 2002; 324: 1287-8
11. National Institute for Clinical Excellence (NICE) Guidance on the use of cyclo-oxygenase (Cox) II selective inhibitors: www.nice.org.uk
12. Fitzgerald GA, Patrono C. The Coxibs, Selective inhibitors of Cyclooxygenase-2 N Engl J Med 2001; 345: 433-42